Introduction {#s1}
============

Endothelial cells (ECs) line the lumen of all blood vessels and are important regulators of artery and arteriole smooth muscle contractility. In capillaries, which lack an overlying smooth muscle cell layer, this regulatory function is absent. In these smallest of all blood vessels, ECs instead support the nutrient- and gas-exchange function characteristic of capillary beds generally. In the brain, capillary ECs (cECs) also constitute the blood-brain barrier, reflecting the presence of tight junctions between adjacent cECs. Not surprisingly given these differing cellular missions, the molecular repertoire of brain cECs and arterial/arteriolar ECs exhibit some marked differences. Notably, intermediate and small-conductance Ca^2+^-activated K^+^ channels (IK and SK, respectively), which are important in transducing elevations in intracellular Ca^2+^ concentration (\[Ca^2+^\]~i~) into membrane potential hyperpolarization in artery/arteriolar ECs to cause relaxation of electrically coupled smooth muscle cells ([@bib25]; [@bib38]; [@bib45]), are absent in brain cECs ([@bib26]). However, signaling through G protein--coupled receptors of the Gα~q/11~-subtype (G~q~PCRs)---an important component of this smooth muscle regulatory axis---is robust in brain cECs ([@bib16]). In the canonical pathway of G~q~PCR signaling, Gα~q~ released upon agonist binding activates phospholipase C (PLC), which hydrolyzes the minor inner leaflet phospholipid, phosphatidylinositol 4,5-bisphosphate (PIP~2~). Breakdown of PIP~2~ yields diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP~3~), the latter of which increases \[Ca^2+^\]~i~ by acting on its cognate receptor (IP~3~R) on the endoplasmic reticulum (ER) to promote Ca^2+^ release from intracellular stores.

Blood delivery within the brain is mediated by an ever-narrowing vascular tree comprising surface arteries, penetrating (parenchymal) arterioles and a vast network of capillaries, which enormously extend the territory of perfusion ([@bib4]). Because the brain lacks substantial energy reserves, it relies on an on-demand mechanism for redistributing oxygen and nutrients to regions of higher neuronal activity, a process in which products released by active neurons trigger a local increase in blood flow. This use-dependent increase in local blood flow (functional hyperemia), mediated by a process termed neurovascular coupling (NVC), is essential for normal brain function ([@bib21]) and represents the physiological basis for functional magnetic resonance imaging ([@bib35]).

We recently reported that brain capillaries act as a neuronal activity-sensing network, demonstrating that brain cECs are capable of initiating an electrical (hyperpolarizing) signal in response to neuronal activity that rapidly propagates upstream to dilate feeding parenchymal arterioles and increase blood flow locally at the site of signal initiation ([@bib26]). We also established the molecular mechanism underlying this process, showing that extracellular K^+^---a byproduct of every neuronal action potential---is the critical mediator and identifying the Kir2.1 channel as the key molecular player ([@bib26]). Kir2.1 channels are activated by external K^+^ and exhibit steep activation by hyperpolarization ([@bib17]; [@bib27]), characteristics that facilitate regenerative K^+^ conductance in neighboring cECs and enable long-range propagation of the hyperpolarizing signal ([@bib26]). Intriguingly, we have since discovered that decreases in capillary endothelial PIP~2~ levels induced by G~q~PCRs agonists suppress Kir2.1 channel currents, reflecting the fact that PIP~2~ is required for Kir2.1 channel activity ([@bib16]). Importantly, this suppressive effect of PIP~2~ depletion exerts a major modulatory influence on K^+^-evoked hyperemic responses in vivo. In addition to regulating Kir2 family members, PIP~2~ has been shown to bind to and regulate a diverse array of ion channels ([@bib19]). Notable in this context, PIP~2~ binding has been shown to inhibit several members of the transient receptor potential (TRP) family of non-selective cation channels, including the vanilloid subtype TRPV4 ([@bib30]; [@bib36]; [@bib44]), which we and others have shown is an important Ca^2+^ influx pathway in arterial and arteriolar ECs ([@bib12]; [@bib39];[@bib38]; [@bib50]).

The Kir2.1 channel appears to be the major K^+^ channel type in brain cECs ([@bib26]). However, the identity of depolarizing (Na^+^/Ca^2+^-permeable) channels in cECs is not known. Here, we show that TRPV4 channels are present in cECs and exhibit an exceedingly low open probability under basal conditions due to tonic inhibition by PIP~2~. We have further found that this inhibition is relieved through PIP~2~ depletion, independent of the action of the PIP~2~ hydrolysis products, DAG and IP~3~. These findings provide a counterpoint to our recent demonstration that Kir2.1 channel activity is sustained by basal levels of PIP~2~ and suppressed by G~q~PCR-mediated PIP~2~ depletion ([@bib16]). Collectively, our findings indicate that PIP~2~ exerts opposite effects on TRPV4 and Kir2.1 channels in brain cECs, demonstrating that a single regulatory pathway governs the balance between two divergent signaling modalities---one depolarizing and the other hyperpolarizing---in the capillary endothelium.

Results {#s2}
=======

TRPV4 channels in brain cECs are inhibited by intracellular ATP {#s2-1}
---------------------------------------------------------------

We previously reported that the selective TRPV4 agonist GSK1016790A (hereafter GSK101) is a potent activator of TRPV4 currents in mesenteric artery ECs that induces maximal arterial dilation at concentrations in the low nanomolar range ([@bib39]; [@bib38]). To assess TRPV4 channel expression and function in brain cECs, we first performed patch-clamp electrophysiology experiments on freshly isolated cECs from C57BL/6J mouse brain slices, prepared as described in Materials and methods. Specifically, we recorded outward K^+^ currents mediated by TRPV4 channels in the cytoplasm-intact, perforated whole-cell configuration using a 300 ms ramp protocol (−100 to +100 mV, from a holding potential of −50 mV). Recordings were made in the presence of the voltage-dependent pore blocker ruthenium red (RuR; 1 µM), an approach we have previously used to assess TRPV4 currents in mesenteric artery ECs ([@bib38]). Under these conditions, depolarizing ramps rapidly displace RuR, allowing unimpeded outward K^+^ currents to be detected while preventing Na^+^/Ca^2+^ influx and associated Ca^2+^ overload and cell death ([@bib38]). Unexpectedly, we found that GSK101 was unable to evoke a detectable whole-cell TRPV4 current in cECs at concentrations that maximally activate TRPV4 channels in mesenteric artery ECs; in fact, even GSK101 concentrations as high as 100 nM failed to stimulate a detectable TRPV4 current in isolated cECs ([Figure 1A](#fig1){ref-type="fig"}). However, we serendipitously found that breaking through the cell membrane from a perforated patch in the presence of an otherwise ineffective GSK101 concentration (100 nM) resulted in the gradual (\~5 min) development of a robust TRPV4 current, suggesting that a factor that suppresses TRPV4 channels had been washed out of the cell.

![Intracellular ATP suppresses TRPV4 currents in cECs.\
(**A**) Representative traces of TRPV4 currents recorded from freshly isolated cECs using voltage ramps (−100 to 100 mV, from a holding potential −50 mV; inset) and different patch-clamp configurations before (black) and after (blue) the application of 100 nM GSK101 and 1 µM RuR. *Top*: Currents recorded in the perforated whole-cell configuration. *Middle*: Currents recorded in the conventional whole-cell configuration (dialyzed cytoplasm, 1 mM Mg-ATP in the pipette solution). *Bottom*: Currents recorded in the conventional whole-cell configuration (0 mM Mg-ATP in the pipette solution) developed gradually over \~4 min. (**B**) Current-voltage relationship (*top*) and summary data (*bottom left*) of currents recorded before (control) and after the cumulative application of GSK101 (100 nM)+RuR (1 µM) followed by HC-067047 (1 µM) (means ± SEM, \*\*\*p\<0.001, unpaired Student's t-test; n = 5 each). *Bottom right*: Individual-value plot of peak outward GSK101 (100 nM)-induced currents in cECs isolated from brains of C57Bl/6 (n = 25) or TRPV4^-/-^ (n = 6) mice. A minimum duration of \~5 min after the application of GSK101 was allowed for outward TRPV4 current to develop in each cEC. Data are presented as means ± SEM (\*\*\*p\<0.001, unpaired Student's t-test). (**C**) Individual-value plot of peak outward currents recorded at 100 mV before and after the application of GSK101 (100 nM) onto cECs dialyzed with 0 or 1 mM Mg-ATP in the pipette solution. Individual data points are shown together with means (column bars) and SEM (error bars). (**D**) Representative traces (*left*) and summary individual-value plot (*right*) of TRPV4 single-channel activity. Single-channel openings of TRPV4 channels were recorded as outward quantal K^+^ currents from cECs in the absence of GSK101 (conventional whole-cell configuration; holding potential, +50 mV; sampling rate, 20 kHz; low-pass filter frequency, 1 kHz; average recording time for each data point, 6 min). cECs were dialyzed with 0 mM (n = 13) or 1 mM (n = 16) Mg-ATP. One group of cECs dialyzed with 0 mM Mg-ATP was treated with 1 µM HC-067047 (n = 5). Data are presented as means (column bars) ± SEM (error bars; \*p\<0.05, \*\*\*p\<0.001, one-way ANOVA followed by Tukey's multiple comparisons test).\
10.7554/eLife.38689.007Figure 1---source data 1.Numerical data that were used to generate the chart in [Figure 1B](#fig1){ref-type="fig"}.\
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In the conventional whole-cell configuration with physiological levels of Mg-ATP (1 mM) included in the patch pipette, application of 100 nM GSK101 also failed to evoke an outward current. In striking contrast, this same concentration of GSK101 caused the gradual (\~4--5 min) development of a robust outward current in the conventional whole-cell configuration when Mg-ATP was omitted from the pipette solution ([Figure 1A](#fig1){ref-type="fig"}). Collectively, these observations suggest that ATP is the suppressive factor in question. Consistent with this interpretation, intracellular Mg-ATP (1 mM) caused a dramatic shift in the sensitivity of cEC TRPV4 channels to GSK101: at a potential of 100 mV, the EC~50~ of GSK101 for TRPV4 channels in the presence of Mg-ATP was 415 nM. However, in the absence of Mg-ATP, the EC~50~ was reduced \~23 fold to 18 nM ([Figure 1C](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1A,B](#fig1s1){ref-type="fig"}), a value comparable to that observed in mesenteric artery ECs ([@bib39]). The suppressive effect of ATP was specific for adenosine nucleotides, as inclusion of 1 mM GTP in the patch pipette did not alter currents ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). GSK101-induced currents were completely abolished by the selective TRPV4 channel antagonist HC-067047 (1 µM) and were absent in cECs from TRPV4-knockout (TRPV4^-/-^) mice ([Figure 1B](#fig1){ref-type="fig"}; [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}), confirming that these currents are attributable to TRPV4 channels. The inhibitory effect of intracellular Mg-ATP (1 mM) was not limited to GSK101-activated TRPV4 currents. As shown ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}), it also suppressed both inward and outward currents in cECs activated by the TRPV4 agonist 4α-phorbol 12,13-didecanoate (4α-PDD; 5 µM, in the absence of RuR).

There was no detectable whole-cell TRPV4 current in the absence of a TRPV4 activator ([Figure 1A](#fig1){ref-type="fig"}), suggesting that these channels have a very low basal open probability. To further investigate this, we monitored single TRPV4 channel openings using dialyzed cECs in the conventional whole-cell configuration, an approach that should allow detection of openings of all channels throughout the cEC plasma membrane while controlling intracellular composition. First, we measured TRPV4 unitary currents in dialyzed cECs (0 mM Mg-ATP) held at +50 mV before and after the application of 100 nM GSK101. The unitary current amplitude in the presence of GSK101, estimated from amplitude histograms, was 4.6 ± 0.3 pA (n = 3) ([Figure 1---figure supplement 3A](#fig1s3){ref-type="fig"}). This value corresponds to a single-channel conductance of 92 ± 6 pS, in line with values reported in an earlier investigation of TRPV4 channels in native arterial ECs ([@bib48]) and heterologous expression systems ([@bib28]). Extending these results, we next performed a series of single-channel recordings in the absence of GSK101. cECs held at +50 mV and dialyzed with Mg-ATP (1 mM) displayed infrequent openings (NP~O~ = 0.038 ± 0.006), but removing ATP increased single-channel opening by \~6 fold (NP~O~ = 0.209 ± 0.044) ([Figure 1D](#fig1){ref-type="fig"}; [Figure 1---source data 3](#fig1sdata3){ref-type="supplementary-material"}). Single-channel openings in the absence of agonist exhibited a unitary current of 4.5 ± 0.3 pA at +50 mV ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 3B](#fig1s3){ref-type="fig"}), similar to that evoked using a specific TRPV4 agonist (4.6 pA) ([Figure 1---figure supplement 3A](#fig1s3){ref-type="fig"}) and corresponding to a conductance of 90 ± 6 pS. Single-channel currents recorded in the absence of GSK101 were inhibited by the TRPV4 blocker HC-067047 (NP~O~ = 0.063 ± 0.028) ([Figure 1D](#fig1){ref-type="fig"}; [Figure 1---source data 3](#fig1sdata3){ref-type="supplementary-material"}), confirming their identity as TRPV4 channel-mediated currents. Based on our estimate of \~225 functional TRPV4 channels per cEC (see Materials and methods), we calculate that capillary TRPV4 channels have a basal open probability (P~O~) of \~0.0002. These observations collectively indicate that capillary TRPV4 channels exhibit a low open probability under basal conditions, and that both constitutive and agonist-induced TRPV4 activities are suppressed by intracellular ATP and recover following ATP washout/dialysis.

TRPV4 channel suppression is dependent on ATP hydrolysis, but independent of protein kinase A, G or C {#s2-2}
-----------------------------------------------------------------------------------------------------

The Mg^2+^ salt of ATP is readily hydrolyzable and can be utilized by kinases ([@bib31]). To test whether TRPV4 suppression requires ATP hydrolysis, we replaced ATP in the patch pipette with the poorly hydrolyzable analog, ATP-γ-S (1 mM). Under these conditions, GSK101 (100 nM) increased TRPV4 currents to same extent as observed in cells dialyzed with 0 mM Mg-ATP, indicating that ATP hydrolysis is required for channel inhibition ([Figure 2A,B](#fig2){ref-type="fig"}; [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). This implies an energy-consuming process, and suggests the involvement of an enzyme, possibly a kinase. Coordination of Mg^2+^ is critical for kinase-mediated phosphoryl transfer reactions ([@bib31]; [@bib37]; [@bib53]). Thus, the prediction is that ATP would be unable to inhibit TPRV4 currents in the absence of the cofactor Mg^2+^ if a kinase underlies Mg-ATP--mediated TRPV4 inhibition. Consistent with this prediction, replacing Mg-ATP in the patch pipette with the Na^+^ salt of ATP (Na-ATP, 1 mM) while eliminating Mg^2+^ from the pipette solution abolished the suppressive effect of ATP ([Figure 2B](#fig2){ref-type="fig"}; [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}), suggesting the contribution of a kinase to this process.

![ATP hydrolysis is required for ATP-mediated suppression of TRPV4 channel activity.\
(**A**) Representative traces of current-voltage relationships in cECs recorded using voltage ramps (−100 to 100 mV) before and after the application of 100 nM GSK101 and 1 µM RuR. cECs were dialyzed with 1 mM Mg-ATP (*left*) or 1 mM Mg-ATP-γ-S (*right*). (**B**) Summary data showing GSK101 (100 nM)-induced outward currents at 100 mV in cECs dialyzed with Mg-ATP (1 mM), Mg-ATP-γ-S (1 mM) or Na-ATP (1 mM, in Mg^2+^ free solution). A minimum duration of 5 min after the application of GSK101 was allowed for outward TRPV4 current to develop in each cEC. Data are presented as means ± SEM (\*\*\*\*p\<0.0001 vs. Mg-ATP, one-way ANOVA followed by Dunnett's multiple comparisons test). (**C**) TRPV4 outward currents induced by 100 nM GSK101 at 100 mV, recorded from dialyzed cECs (0 and 1 mM Mg-ATP). Mg-ATP--dialyzed cECs (gray shadow) were pre-treated with inhibitors of PKA (H-89, 1 µM), PKG (KT5823, 1 µM) or PKC (calphostin C, 0.5 µM) for \~10--15 min prior to GSK101 application, or left untreated (control). Data are presented as means ± SEM (n.s. denotes not significant vs. control Mg-ATP, one-way ANOVA, Dunnett's multiple comparisons test, n = 6--24). (**D**) Summary data showing the effect of raising intracellular Mg-ATP concentration on GSK101-induced TRPV4 currents. Data are means ± SEM (\*\*\*\*p\<0.0001, one-way ANOVA followed by Dunnett's multiple comparisons test).\
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On the basis of these observations, we next tested the involvement of protein kinases by bath-applying the protein kinase A (PKA) inhibitor H-89 (1 µM), protein kinase G (PKG) inhibitor KT5823 (1 µM), or protein kinase C (PKC) inhibitor calphostin C (0.5 µM). We then monitored outward TRPV4-mediated currents as described above. None of these inhibitors affected currents in cells dialyzed with Mg-ATP ([Figure 2C](#fig2){ref-type="fig"}; [Figure 2---source data 2](#fig2sdata2){ref-type="supplementary-material"}), ruling out a role for these protein kinases in TRPV4 inhibition. Further support for this conclusion is provided by the observation that lower concentrations of Mg-ATP (10 and 100 µM)---which activate the majority of protein kinases ([@bib23])---failed to effectively inhibit TRPV4 currents in cECs ([Figure 2D](#fig2){ref-type="fig"}; [Figure 2---source data 3](#fig2sdata3){ref-type="supplementary-material"}).

ATP-dependent suppression of TRPV4 channels is mediated by PIP~2~ {#s2-3}
-----------------------------------------------------------------

Lipid kinases, like protein kinases, also hydrolyze ATP, but typically require higher ATP concentrations ([@bib18]; [@bib23]; [@bib51]). The requirement for millimolar Mg-ATP concentrations to effectively inhibit TRPV4 currents ([Figure 1C](#fig1){ref-type="fig"}, [Figure 2D](#fig2){ref-type="fig"}) is thus more consistent with lower ATP-affinity lipid kinases like those involved in phosphoinositide synthesis ([@bib1]). In this cascade ([Figure 3A](#fig3){ref-type="fig"}), phosphatidylinositol 4-kinase (PI4K) utilizes ATP to phosphorylate phosphatidylinositol (PI), converting it to phosphatidylinositol 4-phosphate (PIP), which in turn is phosphorylated to PIP~2~ by phosphatidylinositol 4-phosphate 5-kinase (PIP5K), a step that also requires ATP. Thus, the cellular levels of PIP~2~ are maintained through an ATP-hydrolysis--dependent process ([@bib2]; [@bib18]; [@bib42]). To assess the possible involvement of this pathway in capillary TRPV4 suppression, we tested the effects of four structurally unrelated pharmacological inhibitors of PI4K: wortmannin (50 µM), PIK93 (300 nM), phenylarsine oxide (PAO; 30 µM), and LY294002 (300 µM). In each case, inhibitors of PIP~2~ synthesis significantly reversed TRPV4 channel inhibition by ATP ([Figure 3B](#fig3){ref-type="fig"}; [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}), despite the high intracellular Mg-ATP concentration (1 mM). Notably, at concentrations below those necessary to inhibit PI4K (but sufficient to suppress phosphoinositide 3-kinases), the inhibitors wortmannin (0.1 µM) and LY294002 (10 µM) failed to increase TRPV4 current in cECs ([Figure 3B](#fig3){ref-type="fig"}; [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). Collectively, these observations indicate the involvement of the ATP/PI4K regulatory axis, and presumably PIP~2~, in suppressing TRPV4 channels in cECs.

![PIP~2~ mediates tonic inhibition of capillary TRPV4 channels.\
(**A**) Schematic diagram showing the ATP-dependent synthesis steps leading to the production of PIP~2~. (**B**) Average maximum outward TRPV4 current induced by 100 nM GSK101, recorded in cECs at 100 mV using the conventional whole-cell configuration. cECs dialyzed with 1 mM Mg-ATP were treated for \~10 min with wortmannin (0.1, 50 µM), PIK93 (0.3 µM), PAO (30 µM) or LY294002 (10, 300 µM), or were left untreated (control). A minimum duration of 10--15 min after the application of GSK101 was allowed for outward TRPV4 current to develop in each cEC. Data are means ± SEM (\*\*p\<0.01, \*p\<0.05 vs. control Mg-ATP, one-way ANOVA followed by Dunnett's multiple comparisons test; n = 6--27). (**C**) Traces of current-voltage relationship obtained from a cEC dialyzed with 10 µM diC8-PIP~2~ and 0 mM Mg-ATP using a voltage ramp (−100 to 100 mV) before and after (green) the application of GSK101 (100 nM) and RuR (1 µM). The dotted gray trace is a representative GSK101-induced current recorded from a control cEC dialyzed with 0 µM diC8-PIP~2~ and 0 mM Mg-ATP. (**D**) Summary data showing GSK101 (100 nM)-induced currents at 100 mV in cECs dialyzed with different concentrations of diC8-PIP~2~ (10, 20, 50 µM) or 0 µM phosphoinositide (control). The pipette solution lacked Mg-ATP in all groups. GSK101-evoked outward currents developed over \~5 min. Data are presented as means ± SEM (\*p\<0.05, *\**\**P*\<0.01, one-way ANOVA followed by Dunnett's multiple comparisons test; n = 10--18). (**E, F**) Representative trace (**E**) and summary data showing GSK101-induced currents in cECs dialyzed with 1 mM Mg-ATP and poly-L-lysine (3 µg/ml). A duration of 10 min was allowed after the application of GSK101 for outward TRPV4 current to develop in each cEC. Data in F are presented as means ± SEM (\*\*p\<0.01, unpaired Student's t-test; n = 8--18).\
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10.7554/eLife.38689.018Figure 3---source data 2.Numerical data that were used to generate the chart in [Figure 3D](#fig3){ref-type="fig"}.\
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PIP~2~ is a well-established regulator of membrane proteins, including ion channels ([@bib19]; [@bib20]; [@bib30]). To directly test whether PIP~2~ inhibits TRPV4 channels in cECs, we introduced the water-soluble, short acyl chain dioctanoyl PIP~2~ (diC8-PIP~2~) via the patch pipette. In the absence of Mg-ATP, diC8-PIP~2~ inhibited GSK101-induced TRPV4 currents, reducing them by 70--80% at concentrations of 10 to 50 µM ([Figure 3C,D](#fig3){ref-type="fig"}; [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}). Similar inhibition was observed with the longer-chain PIP~2~ analog, diC16-PIP~2~ (10 µM) ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Moreover, scavenging endogenous, negatively charged PIP~2~ with intracellular poly-L-lysine (3 µg/ml, molecular weight 15,000--30,000), included in the patch pipette, attenuated Mg-ATP effects on GSK101-induced TRPV4 currents ([Figure 3E,F](#fig3){ref-type="fig"}; [Figure 3---source data 3](#fig3sdata3){ref-type="supplementary-material"}). Taken together, these data show that PIP~2~ inhibits both GSK101-induced and constitutive TRPV4 channel activity in cECs.

G~q~PCR activation relieves TRPV4 suppression in cECs by promoting PIP~2~ hydrolysis {#s2-4}
------------------------------------------------------------------------------------

The primary mechanism responsible for reducing PIP~2~ levels is activation of G~q~PCRs and subsequent PLC-mediated PIP~2~ hydrolysis. To determine whether endothelial G~q~PCR-activation--mediated PIP~2~ depletion relieves the inhibition of TRPV4 channels, we examined the effects of G~q~PCR agonists on constitutive single-channel TRPV4 currents in cECs under simulated physiological conditions (i.e. dialyzed with Mg-ATP) ([Figure 1D](#fig1){ref-type="fig"}). We first tested the effects of prostaglandin E2 (PGE~2~), a postulated NVC agent that acts on G~q~-coupled EP~1~ receptors in cECs to deplete PIP~2~ ([@bib16]) and has previously been proposed to act through G~s~-protein-coupled EP~2~ and EP~4~ receptors to cause vasodilation ([@bib24]; [@bib54]). PGE~2~ significantly increased TRPV4 single-channel open probability in the absence of GSK101 ([Figure 4A,B](#fig4){ref-type="fig"}), increasing NP~O~ \~6 fold ([Figure 4C](#fig4){ref-type="fig"}; [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). This enhancement was similar to that observed under conditions in which intracellular Mg-ATP was excluded from the pipette solution (in the absence of either a receptor agonist or GSK101; [Figure 1D](#fig1){ref-type="fig"}), suggesting that PGE~2~ acts through PIP~2~ depletion to relieve PIP~2~-mediated inhibition and restore TRPV4 channel activity.

![PGE~2~ enhances TRPV4 channel activity.\
(**A**) *Top:* Representative conventional whole-cell recordings from a cEC dialyzed with 1 mM Mg-ATP in the absence of GSK101 and held at a membrane potential of +50 mV. Quantal outward K^+^ currents (unitary current, 4.6 pA; sampling rate, 20 kHz; lowpass filter frequency, 1 kHz), reflecting single-channel openings, were recorded before (baseline) and after the consecutive application of PGE~2~ (2 µM) and HC-067047 (1 µM). *Bottom:* Corresponding amplitude histograms and open probability (NP~O~) values. (**B, C**) Representative trace (**B**) and individual-value plot (**C**) of TRPV4 NP~O~ in cECs (dialyzed with 1 mM Mg-ATP, held at +50 mV) in the absence (control; n = 16) and presence (n = 12) of 2 µM PGE~2~. Data in *C* are means (column bars) ± SEM (error bars, \*\*\*p\<0.001, unpaired Student's t-test). Each data point represents a recording from a cEC; the average duration of each recording was 5 min.\
10.7554/eLife.38689.021Figure 4---source data 1.Numerical data that were used to generate the chart in [Figure 4C](#fig4){ref-type="fig"}.](elife-38689-fig4){#fig4}

To confirm that PIP~2~ depletion underlies PGE~2~-induced activation of TRPV4 channels, we next employed a series of conventional whole-cell recordings and pharmacological interventions to test the different components in the proposed pathway. In these experiments, cECs were dialyzed with 1 mM Mg-ATP---a maneuver sufficient to significantly suppress TRPV4 channels even in the presence of 100 nM GSK101 ([Figure 1A,C](#fig1){ref-type="fig"}). As predicted, application of PGE~2~ (2 µM) in the presence of GSK101 greatly increased TRPV4 currents in cECs dialyzed with Mg-ATP ([Figure 5A,B](#fig5){ref-type="fig"}; [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). Currents evoked by PGE~2~ application were inhibited by the TRPV4 antagonist HC-067047 (1 µM) and were absent in cECs from TRPV4^-/-^ animals, confirming that they are mediated by TRPV4 channels ([Figure 5C](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Introduction of the PIP~2~ analog diC8-PIP~2~ (10 µM) in the pipette solution or inhibition of PLC using U73122 (10 µM)---pharmacological interventions that serve to compensate for or prevent PLC-dependent PIP~2~ degradation, respectively---prevented the increase in TRPV4 currents by PGE~2~ ([Figure 5C](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}; [Figure 5---source data 2](#fig5sdata2){ref-type="supplementary-material"}). The non-selective prostanoid receptor (EP~1~/EP~2~/EP~3~) antagonist AH6809 (10 µM) also prevented this effect of PGE~2~, as did the selective EP~1~ antagonist SC51322 (1 µM), suggesting that PGE~2~ acts through the EP~1~ receptor. U73343, the inactive analog of the PLC inhibitor U73122, did not alter PGE~2~ effects ([Figure 5C](#fig5){ref-type="fig"}; [Figure 5---source data 2](#fig5sdata2){ref-type="supplementary-material"}). Collectively, these observations suggest that PGE~2~ signals through the EP~1~-PLC pathway to deplete PIP~2~ and thereby relieve PIP~2~-mediated TRPV4 inhibition.

![PGE~2~ relieves PIP~2~-mediated TRPV4 channel suppression.\
(**A**) Representative current-voltage plots obtained from a cEC dialyzed with 1 mM Mg-ATP and treated consecutively with GSK101 (100 nM) and RuR (1 µM) followed by 2 µM PGE~2~. (**B**) Summary individual-value plot of GSK101-induced TRPV4 currents at 100 mV in cECs dialyzed with 1 mM Mg-ATP in the absence (black; n = 27) and presence (orange; n = 15) of 2 µM PGE~2~. Incubation of cECs with PGE~2~ lasted \~15 min. Data in *B* are means (column bars) ± SEM (error bars, \*\*\*\*p\<0.0001, unpaired Student's t-test). (**C**) *Top:* Schematic diagram showing the G~q~PCR-dependent hydrolysis of PIP~2~ and the interventions used to test different components of the proposed pathway. *Bottom:* Summary data showing GSK101 (100 nM)-induced currents recorded at 100 mV in cECs dialyzed with 1 mM Mg-ATP. Currents were recorded in the absence and presence of 2 µM PGE~2~ (orange shading), with or without (control) the indicated interventions. Concentrations (and application method): HC-067047, 1 µM (bath); diC8-PIP~2~, 10 µM (pipette), U73122, 10 µM (bath); U73343, 10 µM (bath); AH6809, 10 µM (bath); SC51322, 1 µM (bath); calphostin C, 0.5 µM (bath); Gö6976, 1 µM (bath); CPA, 30 µM (bath); BAPTA, 5.4 mM (pipette). For bath application, pharmacological agents were added 10--15 min before PGE~2~ application.\
10.7554/eLife.38689.025Figure 5---source data 1.Numerical data that were used to generate the chart in [Figure 5B](#fig5){ref-type="fig"}.\
10.7554/eLife.38689.026Figure 5---source data 2.Numerical data that were used to generate the chart in [Figure 5C](#fig5){ref-type="fig"}.](elife-38689-fig5){#fig5}

The PIP~2~ breakdown products, DAG and IP~3~, stimulate PKC activity and promote Ca^2+^ release from the endoplasmic reticulum, respectively. To rule out the involvement of these pathways in the PGE~2~-induced increase in TRPV4 currents, we first tested the effects of the PKC inhibitors, Gö6976 (1 µM) and calphostin C (0.5 µM), and found that neither altered PGE~2~-induced activation of TRPV4 channels ([Figure 5C](#fig5){ref-type="fig"}; [Figure 5---source data 2](#fig5sdata2){ref-type="supplementary-material"}). To determine whether intracellular Ca^2+^ signals downstream of EP~1~-PLC activation by PGE~2~ are involved in TRPV4 disinhibition, we blocked Ca^2+^ reuptake into intracellular stores by inhibiting the sarcoplasmic/endoplasmic reticulum Ca^2+^ ATPase (SERCA) pump with cyclopiazonic acid (CPA; 30 µM) or by rapidly chelating cytoplasmic Ca^2+^ with BAPTA (5.4 mM). Neither maneuver attenuated PGE~2~-induced disinhibition of TRPV4 channel activity ([Figure 5C](#fig5){ref-type="fig"}; [Figure 5---source data 2](#fig5sdata2){ref-type="supplementary-material"}), arguing against a major contribution of DAG-PKC or IP~3~-Ca^2+^ signaling to this effect. Taken together, our data show that PGE~2~ activates EP~1~ receptors and downstream PLC to deplete PIP~2~ and thereby relieve TRPV4 channel inhibition, independently of PIP~2~ metabolites.

Carbachol (10 µM), which can signal through G~q~-coupled muscarinic receptors, induced an increase in TRPV4 currents comparable to that produced by PGE~2~ ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}), indicating that G~q~PCR-mediated TRPV4 activation is not restricted to prostanoid EP~1~ receptors. However, neither the purinergic receptor agonist, ATP (50 µM), nor the protease-activated receptor-2 (PAR2)-activating peptide, SLIGRL-NH~2~ (5 µM), affected TRPV4 channel activity ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). The reason for these apparent differential effects of various G~q~PCRs is currently unclear, but could reflect differences in expression levels or cellular localization of the corresponding receptors, or receptor desensitization owing to ligand-dependent proteolysis (PAR2) or receptor internalization (e.g. P2Y subtypes)([@bib5][@bib6]; [@bib11]; [@bib22]; [@bib40]; [@bib47]).

G~q~PCR signaling as a 'switch' that shifts the balance between TRPV4 and Kir2.1 signaling {#s2-5}
------------------------------------------------------------------------------------------

PIP~2~ levels are key to the maintenance and activation of inward rectifier K^+^ channels, as reported recently by our group ([@bib16]) and others ([@bib9]; [@bib15]; [@bib20]). Our current ([Figure 5](#fig5){ref-type="fig"}) and previous ([@bib16]) findings indicate that G~q~PCR-activation--induced depletion of PIP~2~ exerts opposite effects on endothelial TRPV4 (*activation*) and Kir2.1 (*inhibition*) channels. In fact, G~q~PCR activation in cECs deactivates Kir2.1 currents through PIP~2~ hydrolysis and cripples capillary-to-arteriolar electrical signaling ([@bib16]). It is thus conceivable that G~q~PCR-mediated signaling could shift the balance between TRPV4 and Kir2.1 signaling in brain capillaries through perturbation of endothelial PIP~2~ levels. To test this, we designed an experiment that allowed simultaneous monitoring of TRPV4 and Kir2.1 currents in the context of G~q~PCR-mediated changes in endothelial PIP~2~ levels. Using the perforated-patch configuration to maintain physiological levels of ATP and PIP~2~, and bathing cECs in a solution containing an extracellular K^+^ concentration (\[K^+^\]~o~) of 60 mM to facilitate monitoring of Kir2.1 currents, we evoked TRPV4 currents with 2 µM GSK101, a concentration sufficient to sub-maximally activate an outward current in this configuration (in the presence of 1 µM RuR to block inward TRPV4 current). In this setting, application of PGE~2~ (2 µM) enhanced TRPV4 currents and simultaneously inhibited Kir2.1 currents ([Figure 6A,B](#fig6){ref-type="fig"}; [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}) compared with matching time controls, which showed no significant change in either current ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). The onset of changes in TRPV4 and Kir2.1 currents in response to PGE~2~ was rapid (\<60 s). A kinetic analysis revealed that TRPV4 activation and Kir2.1 suppression were kinetically comparable, with times for half-maximal change in activity (*t*~0.5~) of 3.4 min for TRPV4 and 4.4 min for Kir2.1 channels, and corresponding time constants (τ) of 4.9 and 6.4 min, respectively ([Figure 6C](#fig6){ref-type="fig"}; [Figure 6---source data 2](#fig6sdata2){ref-type="supplementary-material"}). The muscarinic receptor agonist carbachol (10 µM) similarly facilitated TRPV4 currents and inhibited Kir2.1 currents ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). In contrast, purinergic receptor stimulation with ATP did not affect TRPV4 currents ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}; [Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}) despite inhibiting Kir2.1 currents ([Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}), as we reported previously ([@bib16]). These findings collectively establish a potential mechanism by which PGE~2~ or other suitable G~q~PCR agonists, could alter the balance between electrical (hyperpolarizing) signaling mediated by Kir2.1 channels and TRPV4 channel signaling in capillaries through modulation of PIP~2~ levels ([Figure 7](#fig7){ref-type="fig"}).

![PGE~2~ simultaneously and reciprocally regulates TRPV4 and Kir2.1 channel activities.\
(**A**) Representative traces illustrate simultaneous recordings of Kir2.1 (inward) and TRPV4 (outward) currents in a cEC obtained using the perforated whole-cell configuration. Voltage ramps (300 ms, −140 to 100 mV) were used and the cEC was bathed in a 60 mM \[K^+^\]~o~ solution supplemented with 2 µM GSK101 and 1 µM RuR. Traces represent currents before and for a duration of 15 min after the application of 2 µM PGE~2~. (**B**) Averaged current-voltage relationship (n = 5 cECs) corresponding to the experiment in *A*, before (control) and after (maximum changes at 15 min) application of PGE~2~. (**C**) Summary data showing the kinetics of TRPV4 current enhancement (black) and Kir2.1 current decline (red) following application of 2 µM PGE~2~ onto cECs (as in *A*) at room temperature. Points are average percentage change in normalized currents before and over 15 min after PGE~2~ application (n = 5). Curves are best fits of exponential change (rise: TRPV4; decay: Kir2.1). *Inset table:* kinetic parameters based on the two curve fits. Changes in currents plateaued \~13 min after the application of PGE~2~.\
10.7554/eLife.38689.031Figure 6---source data 1.Numerical data that were used to generate the chart in [Figure 6B](#fig6){ref-type="fig"}.\
10.7554/eLife.38689.032Figure 6---source data 2.Numerical data that were used to generate the chart in [Figure 6C](#fig6){ref-type="fig"}.](elife-38689-fig6){#fig6}

![Cartoon representation of G~q~PCR-mediated reciprocal effects on capillary ion channel activity.\
Schematic diagram summarizing the proposed mechanism. *Top*: In the absence of G~q~PCR stimulation, endogenous PIP~2~ levels are sufficient to tonically inhibit TRPV4 channels and maintain Kir2.1 channel activity. *Bottom*: G~q~PCR activation with an agonist stimulates PIP~2~ hydrolysis, resulting in the loss of PIP~2~-mediated maintenance of Kir2.1 activity and inhibition of TRPV4 activity.](elife-38689-fig7){#fig7}

Discussion {#s3}
==========

We previously demonstrated that increases in \[K^+^\]~o~ associated with neuronal activity alter cerebral blood flow at the capillary level, showing that extracellular K^+^ activates capillary Kir2.1 channels, triggering a retrograde electrical (hyperpolarizing) signal that propagates upstream to dilate feeding arterioles and enhance blood flow to the active region ([@bib26]). We have also shown that G~q~PCR-mediated PIP~2~ depletion inhibits capillary electrical signaling ([@bib16]), identifying a point of intersection between electrical signaling and endothelial G~q~PCR activity. In the present study, we show that cECs express TRPV4 channels, and demonstrate that these channels are tonically suppressed by basal levels of PIP~2~. Furthermore, we show that G~q~PCR activation relieves TRPV4 channel inhibition through PIP~2~ depletion. This paradigm introduces the phosphoinositide PIP~2~ as a master regulator of TRPV4 and Kir2.1 signaling in the capillary endothelium and highlights the ability of G~q~PCR activity to tune the balance of these signaling modalities to favor TRPV4 signaling ([Figure 7](#fig7){ref-type="fig"}).

The repertoire of functional ion channels in brain cECs remains incompletely characterized, although certain molecular features have recently come into focus. For instance, our evidence suggests that the inward rectifier Kir2.1 channel is the major K^+^ channel type in brain cECs ([@bib26]), whereas Ca^2+^-sensitive SK and IK channels, which are present in arterial and arteriolar ECs and play a prominent role in regulating vascular tone ([@bib25]; [@bib38]; [@bib45]), are not expressed in brain cECs ([@bib26]). Notably, the identity of depolarizing (Na^+^ and/or Ca^2+^-permeable) channels in cECs, which we predict must be present to allow the membrane potential to reset to support repeated operation of our previously reported Kir2.1-dependent electrical signaling-based NVC mechanism, is not known. Our demonstration that the highly selective TRPV4 agonist, GSK101, induced currents in brain cECs that were eliminated by the TRPV4-specific antagonist, HC-067047, and were absent in cECs from TRPV4^-/-^ mice firmly establishes the presence of this non-selective cation channel in capillaries. In arterial and arteriolar ECs, TRPV4 channel-mediated Ca^2+^ influx is closely linked to activation of Ca^2+^-sensitive SK and IK channels and subsequent membrane potential hyperpolarization ([@bib38]). However, because cECs lack functional Ca^2+^-activated K^+^ channels ([@bib26]), TRPV4-mediated influx of Na^+^/Ca^2+^ in these cells instead would lead to membrane potential depolarization ([@bib3]; [@bib12]). Collectively, these observations suggest that the TRPV4 channel is a major depolarizing element in cECs, although we cannot rule out the possibility that other, as yet unidentified, cation channels may contribute to membrane depolarization, as suggested by earlier studies ([@bib8]; [@bib34]; [@bib7]). Our observations also highlight the fact that the functional role of TRPV4 channels is critically dependent on the expression and function of key associated proteins.

Intriguingly, and in striking contrast to the case in peripheral arterial ECs ([@bib39]; [@bib38]), the open probability of capillary TRPV4 channels in cECs was remarkably low under basal conditions and was increased by dialyzing out intracellular contents---the first link in the chain leading to our discovery that TRPV4 channels in cECs are intrinsically inhibited by intracellular ATP. It is well established that lipid kinases involved in PIP~2~ synthesis require millimolar ATP for their activity ([@bib1]; [@bib18]; [@bib23]; [@bib41]), and it has been amply demonstrated that PIP~2~ maintenance is dependent on ATP in multiple cell types ([@bib43]; [@bib52]; [@bib53]), including cECs ([@bib16]). Three major lines of evidence presented here support the conclusion that cytosolic ATP-dependent maintenance of sustained, basal levels of PIP~2~ suppresses TRPV4 channel activity. First, millimolar concentrations of hydrolyzable ATP suppressed capillary TRPV4 channel activity. Second, inclusion of PIP~2~ analogs in the patch pipette inhibited TRPV4 currents. Third, scavenging PIP~2~ or inhibiting its synthesis abrogated ATP-mediated inhibition. Notably, PIP~2~ has been reported to directly interact with different residues on the TRPV4 N-terminus in heterologous expression systems ([@bib14]; [@bib44]). However, these studies reached discrepant conclusions, with one suggesting that direct binding of PIP~2~ to the ankyrin repeat domain of the TRPV4 channel inhibits different modes of TRPV4 activation ([@bib44]) and the other reporting that PIP~2~ is necessary for heat-, hypotonicity- or epoxyeicosatrienoic acid (EET)-induced channel activation by facilitating structural rearrangements of the channel ([@bib14]). These discrepancies may reflect divergent effects of PIP~2~ on channel behavior through binding to multiple sites in the channel. Intriguingly, the putative endogenous TRPV4 channel activator ([@bib12]; [@bib49]) 11,12-epoxyeicosatrienoic acid (11,12-EET, 1 µM) evoked currents in cECs even in the absence of dialyzed PIP~2~ ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). In any case, our results are the first to report PIP~2~-mediated suppression of TRPV4 channels in the endothelium and more broadly in native cells and are congruent with the results of [@bib44]. Interestingly, a recent study provided structural evidence that lipid molecules are tightly bound to the selectivity filter of the TRPV4 channel pore, although the identity and function of these lipids were not characterized ([@bib10]).

Canonical G~q~PCR signaling involves PLC activation and subsequent PIP~2~ breakdown into DAG and IP~3~. Receptor agonists that activate G~q~PCRs can dramatically lower PIP~2~ by promoting its hydrolysis at rates that exceed those of PIP~2~ re-synthesis. We show here that PGE~2~, which has previously been postulated to act as an NVC agent through actions on G~s~-coupled EP~2~/EP~4~ receptors in arteriolar smooth muscle ([@bib24]; [@bib54]), activates TRPV4 channels in cECs independent of the action of the PIP~2~ metabolites, DAG and IP~3~, by relieving PIP~2~-mediated suppression ([Figure 4](#fig4){ref-type="fig"}, [Figure 5](#fig5){ref-type="fig"}). In contrast, we recently showed that G~q~PCR agonists exert the opposite effect on capillary Kir2.1 channels, inhibiting their ability to mediate capillary-to-arteriole electrical signaling ([@bib16]). In keeping with these previous findings and our current observations, simultaneous monitoring of TRPV4 and Kir2.1 channel currents confirmed the bidirectional effects of G~q~PCR agonists on the two channels ([Figure 6](#fig6){ref-type="fig"}). This two-way modulation ([Figure 7](#fig7){ref-type="fig"}) is unique as it indicates that a single G~q~PCR signaling cascade is capable of altering the balance between electrical Kir2.1 signaling (*inhibition*) and TRPV4 signaling (*facilitation*). Given the absence of Ca^2+^-activated K^+^ channels in cECs, noted above, G~q~PCR signaling-induced PIP~2~ depletion would likely depolarize cECs through the simultaneous disinhibition of depolarizing TRPV4 channels (this study) and deactivation of hyperpolarizing Kir2.1 channels ([@bib16]).

Based on our direct Kir2.1 current measurements ([@bib16]; [@bib26]) and the known voltage- and K^+^-dependence of Kir2.1 channels ([@bib27]), we estimate that the outward current through these channels at physiological membrane potentials (about −40 mV) and external K^+^ (3 mM) is \~6 fA. Elevation of external K^+^ to 10 mM would increase Kir2 current at this voltage to \~260 fA. Though seemingly miniscule, such small membrane currents are precisely what is needed to ensure conduction fidelity. We have measured a sustained and profound hyperpolarization of about −25 mV in arteriolar smooth muscle in response to capillary stimulation with 10 mM K^+^ ([@bib26]). Our computational modeling indicates that a stable membrane hyperpolarization of 25 mV requires the outward (hyperpolarizing) current to greatly exceed the inward (depolarizing) current. Our estimate of basal, PIP~2~-suppressed TRPV4 current at −40 mV is about −80 fA. G~q~PCR activation increases open probability \~6 fold, producing a current (400--500 fA) sufficient to effectively short circuit K^+^-induced hyperpolarization and cripple this key Kir2.1-based NVC mechanism. In conclusion, the low level of TRPV4 channel activity aligns with the functional role of capillaries.

Activation of capillary G~q~PCRs should also trigger Ca^2+^ signals in cECs, presumably through IP~3~-mediated Ca^2+^ release from intracellular stores as well as disinhibition of TRPV4 channels (as described here) and subsequent Ca^2+^ influx. Such capillary Ca^2+^ signals should positively influence hemodynamics---and thus functional hyperemia---providing a plausible explanation for the role of G~q~PCR agonists in the NVC process, presumably through the Ca^2+^-dependent activation of nitric oxide synthase (NOS) and subsequent release of the vasodilator, NO ([@bib13]; [@bib29]). Capillary Ca^2+^ signaling might also serve an entirely different purpose in functional hyperemia: because local Ca^2+^ signals represent sites of PIP~2~ depletion (through G~q~PCR signaling), and thus membrane potential depolarization (through TRPV4 disinhibition and Kir2.1 deactivation), they are likely to interfere with the progression of electrical signals generated further down the vascular tree. Accordingly, these signals may represent 'stop signs' or 'speed bumps' that play a role in redirecting hyperpolarizing (vasodilatory) signals away from certain brain areas, in addition to their role in resetting the capillary membrane potential, noted above.

Given the role of PIP~2~ in negatively regulating TRPV4 channels, the exceedingly low basal TRPV4 activity and diminished sensitivity to GSK101 in cECs ([Figure 1](#fig1){ref-type="fig"}) compared with mesenteric artery ECs ([@bib38]) suggest differences in the PIP~2~ 'set point' in these two vascular beds. This supposition has important physiological implications for electrical signaling in the brain. Our data suggest that PIP~2~ levels in brain cECs are sufficient to saturate Kir2.1 channels ([@bib16]) and tune TRPV4 channel currents to levels that prevent inappropriate depolarization of the membrane potential ([Figure 3](#fig3){ref-type="fig"}). In the absence of PIP~2~ suppression of TRPV4 channel-mediated inward currents, it is unlikely that increased outward K^+^ currents through Kir2.1 channels in response to elevated K^+^ would be sufficient to cause membrane potential hyperpolarization. The mechanistic basis for the apparently higher PIP~2~ set point in brain cECs is currently unknown, but could include lower constitutive G~q~PCR activity, lower microenvironmental levels of G~q~PCR agonists and/or decreased G~q~PCR expression---and thus diminished PIP~2~ breakdown. Along these lines, a recent single-cell transcriptomics analysis showed that Gα~q~ (*Gnaq*) transcript levels in the mouse brain endothelium are reduced compared with those in peripheral pulmonary ECs ([@bib47]). Alternatively, differences in the set point could be indicative of more robust PIP~2~ synthesis in brain capillaries, a speculation that is supported by the higher mitochondrial content---and hence ATP synthesis---in highly active brain cECs compared with other ECs ([@bib32]; [@bib33]).

In conclusion, this study provides compelling evidence that brain capillaries express TRPV4 channels and further shows that the activity of these channels is physiologically suppressed by basal levels of PIP~2~. This introduces PIP~2~ and its modulation by G~q~PCR agonists as major regulators of brain capillary signaling. When maintained at sufficient levels, PIP~2~ inhibits TRPV4 channels and supports capillary-to-arteriole electrical signaling, but in response to G~q~PCR activation, PIP~2~ levels are reduced, enhancing TRPV4 signaling and inhibiting retrograde electrical signaling via Kir2.1 channels. Capillary G~q~PCRs can therefore be envisioned as molecular switches that dictate the signaling modality in the brain microvasculature.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species) or resource   Designation                  Source or reference   Identifiers                                                                         Additional information
  ------------------------------------ ---------------------------- --------------------- ----------------------------------------------------------------------------------- ------------------------
  Strain, strain background\           TRPV4 Knockout\              [@bib46])             PMID: 18499743                                                                      
  (*Mus musculus*, males)              (TRPV4^-/-^) mice,\                                                                                                                    
                                       C57BL/6J background                                                                                                                    

  Strain, strain background\           C57BL/6J                     The Jackson\          RRID:[IMSR_JAX:000664](https://scicrunch.org/resolver/IMSR_JAX:000664)              
  (*Mus musculus*, males)                                           Laboratory                                                                                                

  Chemical compound,\                  GSK1016790A\                 Sigma                 Cat\#: G0798                                                                        
  drug                                 (GSK101)                                                                                                                               

  Chemical compound,\                  Ruthenium red (RuR)          Sigma                 Cat\#: R2751                                                                        
  drug                                                                                                                                                                        

  Chemical compound,\                  Adenosine\                   Sigma                 Cat\#: A9187                                                                        
  drug                                 5′-triphosphate\                                                                                                                       
                                       magnesium salt\                                                                                                                        
                                       (Mg-ATP)                                                                                                                               

  Chemical compound,\                  Adenosine\                   Sigma                 Cat\#: A2383                                                                        
  drug                                 5′-triphosphate\                                                                                                                       
                                       sodium salt                                                                                                                            

  Chemical compound,\                  HC-067047                    Sigma                 Cat\#: SML0143                                                                      
  drug                                                                                                                                                                        

  Chemical compound,\                  KT5823                       Sigma                 Cat\#: K1388                                                                        
  drug                                                                                                                                                                        

  Chemical compound, drug              PIK93                        Tocris                Cat\#: 6440                                                                         

  Chemical compound,\                  Phenylarsine oxide\          Sigma                 Cat\# P3075                                                                         
  drug                                 (PAO)                                                                                                                                  

  Chemical compound,\                  H-89 dihydrochloride         Tocris                Cat\# 2910                                                                          
  drug                                                                                                                                                                        

  Chemical compound,\                  Calphostin C                 Tocris                Cat\#: 1626                                                                         
  drug                                                                                                                                                                        

  Chemical compound,\                  LY294002\                    Tocris                Cat\#: 1130                                                                         
  drug                                 hydrochloride                                                                                                                          

  Chemical compound,\                  AH6809                       Tocris                Cat\#: 0671                                                                         
  drug                                                                                                                                                                        

  Chemical compound,\                  SC51322                      Tocris                Cat\#: 2791                                                                         
  drug                                                                                                                                                                        

  Chemical compound,\                  U-73122                      Sigma                 Cat\#: U6756                                                                        
  drug                                                                                                                                                                        

  Chemical compound,\                  U-73343                      Sigma                 Cat\#: U6881                                                                        
  drug                                                                                                                                                                        

  Chemical compound,\                  Poly-L-lysine\               Sigma                 Cat\# 2658                                                                          
  drug                                 hydrochloride                                                                                                                          

  Chemical compound,\                  Gö6976                       Calbiochem            Cat\#: 365250                                                                       
  drug                                                                                                                                                                        

  Chemical compound,\                  Wortmannin                   Sigma                 Cat\#: W1628                                                                        
  drug                                                                                                                                                                        

  Chemical compound,\                  PI(4,5)P2\                   Cayman                Cat\#: 64910                                                                        
  drug                                 (1,2-dioctanoyl)\                                                                                                                      
                                       (sodium salt)                                                                                                                          

  Chemical compound,\                  PI(4,5)P2\                   Cayman                Cat\#: 10008115                                                                     
  drug                                 (1,2-dipalmitoyl)\                                                                                                                     
                                       (sodium salt)                                                                                                                          

  Chemical compound,\                  Prostaglandin E~2~           Sigma                 Cat\#: 5640                                                                         
  drug                                                                                                                                                                        

  Chemical compound,\                  SLIGRL-NH2                   Tocris                Cat\#: 1468                                                                         
  drug                                                                                                                                                                        

  Chemical compound,\                  Carbachol                    Sigma                 Cat\#: C4382                                                                        
  drug                                                                                                                                                                        

  Chemical compound,\                  Cyclopiazonic\               Sigma                 Cat\#: C1530                                                                        
  drug                                 acid from\                                                                                                                             
                                       *Penicillium cyclopium*\                                                                                                               
                                       (CPA)                                                                                                                                  

  Chemical compound,\                  Guanosine\                   Sigma                 Cat\#: G8877                                                                        
  drug                                 5′-triphosphate\                                                                                                                       
                                       sodium salt (GTP)                                                                                                                      

  Chemical compound,\                  Adenosine\                   Sigma                 Cat\#: A1388                                                                        
  drug                                 5′-\[γ-thio\]triphosphate\                                                                                                             
                                       tetralithium salt                                                                                                                      

  Chemical compound,\                  11,12-Epoxyeico\             Sigma                 Cat\#: E5641                                                                        
  drug                                 satrienoic acid\                                                                                                                       
                                       (11,12-EET)                                                                                                                            

  Chemical compound,\                  4α-Phorbol 12,13-\           Sigma                 Cat\#: P8014                                                                        
  drug                                 didecanoate (4α-PDD)                                                                                                                   

  Chemical compound,\                  1,2-Bis\                     Sigma                 Cat\#: A9801                                                                        
  drug                                 (2-aminophenoxy)\                                                                                                                      
                                       ethane-N,N,N′,N′-\                                                                                                                     
                                       tetraacetic\                                                                                                                           
                                       acid tetrapotassium\                                                                                                                   
                                       salt (BAPTA)                                                                                                                           

  Software, algorithm                  Prism                        GraphPad              RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)\                       
                                                                                          [https://www.graphpad.com/](https://www.graphpad.com/scientific-software/prism/)\   
                                                                                          [scientific-software/prism/](https://www.graphpad.com/scientific-software/prism/)   

  Software, algorithm                  Clampfit 10.7                Axon Instruments      RRID:[SCR_011323](https://scicrunch.org/resolver/SCR_011323)\                       
                                                                                          <https://www.moleculardevices.com/products/axon-patch-clamp-system>                 
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Animals {#s4-1}
-------

All procedures involving animals received prior approval from the University of Vermont Institutional Animal Care and Use Committee. Adult (2--3 month old) male C57BL/6J mice (Jackson Laboratories, USA) and TRPV4^-/-^ mice ([@bib46]) were group-housed on a 12 hr light:dark cycle with environmental enrichment and free access to food and water. Animals were euthanized by intraperitoneal injection of sodium pentobarbital (100 mg/kg) followed by rapid decapitation.

Chemicals {#s4-2}
---------

1,2-Dioctanoyl phosphatidylinositol 4,5-bisphosphate sodium salt (diC8-PIP~2~) and 1,2-dipalmitoyl phosphatidylinositol 4,5-bisphosphate sodium salt (diC16-PIP~2~) were purchased from Cayman Chemical (USA). 12-(2-Cyanoethyl)−6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4 c)-carbazole (Gö6976) was from Calbiochem (USA). *N*-((1*S*)−1-{\[4-((2*S*)−2-{\[(2,4-Dichlorophenyl) sulfonyl\] amino}−3-hydroxy-propanoyl)−1-piperazinyl\]carbonyl}−3-methylbutyl)−1-benzothiophene-2-carboxamide (GSK101) and 2-Methyl-1-\[3-(4-morpholinyl)propyl\]−5-phenyl-*N*-\[3-(trifluoromethyl)phenyl\]−1*H*--pyrrole-3-carboxamide (HC-067047) were obtained from Sigma-Aldrich (USA). 6-Isopropoxy-9-xanthone-2-carboxylic acid (AH6809), 8-chloro-2-\[3-\[(2-furanylmethyl)thio\]−1-oxopropyl\]-dibenz(*Z*)\[*b*,*f*\]\[1,4\]oxazepine-10(11*H*)-carboxylic acid hydrazide (SC51322), *N*-\[2-\[\[3-(4-bromophenyl)−2-propenyl\]amino\]ethyl\]−5-isoquinolinesulfonamide dihydrochloride (H-89), (1*R*)−2-\[12-\[(2*R*)−2-(benzoyloxy)propyl\]−3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylenyl\]−1-methylethylcarbonic acid 4-hydroxyphenyl ester (calphostin C), and 2-(4-morpholinyl)−8-phenyl-4*H*-1-benzopyran-4-one hydrochloride (LY 294002) were purchased from Tocris (USA). Unless otherwise noted, all other chemicals were obtained from Sigma-Aldrich.

Capillary endothelial cell isolation {#s4-3}
------------------------------------

Single ECs and capillary fragments were obtained from mouse brains by mechanical disruption of two 160 μm--thick brain slices using a Dounce homogenizer. Slices were homogenized in ice-cold artificial cerebrospinal fluid (124 mM NaCl, 3 mM KCl, 2 mM CaCl~2~, 2 mM MgCl~2~, 1.25 mM NaH~2~PO~4~, 26 mM NaHCO~3~, 4 mM glucose), and debris was removed by passing the homogenate through a 62 µm nylon mesh. Retained capillary fragments were eluted into dissociation solution composed of 55 mM NaCl, 80 mM Na-glutamate, 5.6 mM KCl, 2 mM MgCl~2~, 4 mM glucose and 10 mM HEPES (pH 7.3), containing neutral protease (0.5 mg/mL) and elastase (0.5 mg/mL) (Worthington, USA) plus 100 µM CaCl~2~, and incubated for 24 min at 37°C. Thereafter, 0.5 mg/ml collagenase type I (Worthington) was added and the sample was incubated for an additional 2 min at 37°C. The cell suspension was filtered and the residue was washed to remove enzymes. Single cells and small capillary fragments were dispersed by triturating 4--6 times with a fire-polished glass Pasteur pipette. Cells were stored in ice-cold isolation medium for use the same day (within \~6 hr).

Electrophysiology {#s4-4}
-----------------

All patch-clamp electrophysiological recordings were performed at room temperature (∼22°C) in either the conventional or perforated whole-cell configuration. Currents were amplified using an Axopatch 200B amplifier, filtered at 1 kHz, digitized at 10 kHz, and stored on a computer for offline analysis with Clampfit 10.5 software. Recording pipettes were fabricated by pulling borosilicate glass (1.5 mm outer diameter, 1.17 mm inner diameter; Sutter Instruments, USA) using a Narishige puller. Pipettes were fire-polished to reach a tip resistance of \~4--6 MΩ. The bath solution consisted of 80 or 134 mM NaCl, 60 or 6 mM KCl, 1 mM MgCl~2~, 10 mM HEPES, 4 mM glucose, and 2 mM CaCl~2~ (pH 7.4). For the conventional whole-cell configuration, pipettes were backfilled with a solution consisting of 10 mM NaOH, 11.4 mM KOH, 128.6 mM KCl, 1.1 mM MgCl~2~, 2.2 mM CaCl~2~, 5 mM EGTA, and 10 mM HEPES (pH 7.2). A subset of experiments utilized a Mg^2+^-free solution, obtained by excluding MgCl~2~ from the pipette solution. In another group of cells, EGTA was replaced with BAPTA (5.4 mM). For perforated-patch electrophysiology, the pipette solution was composed of 10 mM NaCl, 26.6 mM KCl, 110 mM K^+^ aspartate, 1 mM MgCl~2~ and 10 mM HEPES; amphotericin B (200--250 µg/ml) was freshly added on the day of the experiment. Whole-cell capacitance, measured using the cancellation circuitry in the voltage-clamp amplifier, averaged 8.6 pF.

Calculation of TRPV4 channel numbers {#s4-5}
------------------------------------

TRPV4 membrane currents were measured using the conventional whole-cell configuration and physiological concentrations of salts. Ruthenium red (RuR; 1 µM) was used to block Ca^2+^ influx and thereby prevent Ca^2+^ overload. We have shown previously that RuR causes a voltage-dependent block of TRPV channels and is rapidly driven out of the pore by membrane depolarization; at +100 mV, RuR (1 µM) blocks approximately 19% of the TRPV4 current ([@bib38]). The number of TRPV4 channels activated by 100 nM GSK101 was estimated by dividing the GSK101-induced current at +100 mV by the unitary current at this voltage (i.e. 10 pA) ([@bib28]; [@bib48]) and correcting for the degree of RuR block.

Data analysis {#s4-6}
-------------

Data are expressed as means ± standard error of the mean (SEM). Effects of a given condition/treatment on whole-cell current were compared using paired or unpaired *t* tests or analysis of variance (ANOVA), as appropriate, using Graphpad Prism 7.01 software. p values≤0.05 were considered statistically significant. Additional patch-clamp data analyses were performed using Clampfit 10.5 software.
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Decision letter
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László

Reviewing Editor

Semmelweis University

Hungary

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"PIP~2~ depletion promotes TRPV4 channel activity in brain capillary endothelial cells\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including László Csanády as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Richard Aldrich as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Tibor Rohacs (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The work by Harraz et al. investigates regulation of TRPV4 channel activity in brain capillary endothelial cells. The authors show that dialysis of the cells with hydrolyzable (Mg salt), but not with non-hydrolyzable (Na salt, ATP-γ-S) forms of ATP tonically suppresses TRPV4 currents. Using specific inhibitors of various protein and lipid kinases they demonstrate that the inhibition requires the activity of phosphatidyl inositol kinases, suggesting that it is mediated by PIP~2~. Indeed, cell dialysis with PIP~2~ causes TRPV4 inhibition even in the absence of Mg-ATP, and dialysis with the PIP~2~-scavenger polylysine reduces tonic inhibition by endogenous PIP~2~ even in the presence of ATP. Finally, they show that extracellular application of the G~q~PCR agonists PGE~2~ or carbachol potentiates TRPV4 activity, and this effect can be specifically abolished by pharmacological agents that inhibit individual components of the G~q~PCR-PLC pathway. Given the contradictory earlier reports of the effects of PIP~2~ on TRPV4 (activating vs. inhibiting), the use of complementary approaches is important. Another strength of the manuscript is that they study exclusively native cells, and use both TRPV4 inhibitors and a TRPV4 -/- mouse to demonstrate that the currents they measure are indeed mediated by TRPV4.

The data are of high quality, and support the authors\' conclusions. Together with previous work by the authors (Harraz et al., 2018) the present work suggests that PIP~2~ depletion reciprocally regulates the hyperpolarizing Kir2.1 and the depolarizing TRPV4 current in brain capillary endothelial cells, identifying these as molecular players involved in the initiation and/or propagation of the vasodilation observed during functional hyperemia. All in all, this is a beautiful study which promotes mechanistic understanding of the process of neurovascular coupling in the brain, and is highly suitable for publication in *eLife*.

Essential revisions:

1\) Experimental:

What is the natural activator of TRPV4 in brain cECs? Even upon PIP~2~ depletion whole-cell NP~o~ is only \~0.2 (amounting to a single-channel P~o~ of \~0.001), which is negligible channel activity. Thus, there must be a natural activator to induce TRPV4 currents in vivo. The authors use exclusively GSK101 as an agonist. In an earlier paper Garcia-Elias et al. (2013) showed that TRPV4 currents induced by heat and osmotic swelling (but not by 4aPDD) were inhibited by selective depletion of PIP~2~ using a chemically inducible lipid phosphatase. Given these contradictory results on positive vs. negative effects of PIP~2~ on TRPV4 channels it would be important to test whether the differential effects of PIP~2~ are due to different modes of activation, or to different cellular environments. e.g., are native TRPV4 channels activated by heat (Garcia-Elias used 38^o^C as stimulus), swelling, or epoxyeicosatrienoic acids (EETs; see Discussion, fifth paragraph) also suppressed by PIP~2~? Specifically, we would like to see experiments similar to those in Figure 5, but in the absence of GSK101, using a more \"natural\" way to activate TRPV4: e.g., body temperature+PGE~2~, or body temperature+EET -- preferably both with and without diC8-PIP~2~ in the pipette.

2\) Discussion:

In a previous study, the group demonstrated that extracellular K^+^ increases activate cEC Kir channels resulting in an upstream hyperpolarizing current which mediated capillary-to-arteriole dilation (Nat. Neurosci, 2017). In a follow up study, the authors showed that PIP~2~ is a molecular regulator of Kir2.1 channels and that G~q~PCR activation impairs capillary-to-arteriole electrical signaling by depleting PIP~2~ (PNAS, 2018). In the current study the idea that G~q~PCR signaling can regulate (via PIP~2~) the activation of opposing signaling pathways suggests that activation of these receptors stops neuronal activity-evoked changes in blood flow. However, this is contradictory to earlier evidence by Lacroix et al. (2015), demonstrating an important role for COX-2 derived PGE~2~ in the NVC response. The authors cite this work, but do not explain how their proposed mechanism relates to the published findings on PGE2 and/or other G~q~PCR agonists. Would all G~q~PCR impair or retard the upstream hyperpolarization initiated by K^+^? Would this pathway be more relevant during pronounced ischemia? Or is it relevant under physiologic conditions? A thorough investigation of this question is beyond the scope of the present work, but a more detailed discussion of unresolved issues would be appreciated.

10.7554/eLife.38689.041

Author response

> Essential revisions:
>
> 1\) Experimental:
>
> What is the natural activator of TRPV4 in brain cECs? Even upon PIP~2~ depletion whole-cell NP~o~ is only \~0.2 (amounting to a single-channel P~o~ of \~0.001), which is negligible channel activity. Thus, there must be a natural activator to induce TRPV4 currents in vivo. The authors use exclusively GSK101 as an agonist. In an earlier paper Garcia-Elias et al. (2013) showed that TRPV4 currents induced by heat and osmotic swelling (but not by 4aPDD) were inhibited by selective depletion of PIP~2~ using a chemically inducible lipid phosphatase. Given these contradictory results on positive vs. negative effects of PIP~2~ on TRPV4 channels it would be important to test whether the differential effects of PIP~2~ are due to different modes of activation, or to different cellular environments. e.g., are native TRPV4 channels activated by heat (Garcia-Elias used 38C as stimulus), swelling, or epoxyeicosatrienoic acids (EETs; see Discussion, fifth paragraph) also suppressed by PIP~2~? Specifically, we would like to see experiments similar to those in Figure 5, but in the absence of GSK101, using a more \"natural\" way to activate TRPV4: e.g., body temperature+PGE~2~, or body temperature+EET -- preferably both with and without diC8-PIP~2~ in the pipette.

We thank the reviewers for affording us the opportunity to address this question in some detail. The question itself requires a bit of unpacking:

1\) "What is the natural activator of TRPV4 in brain cECs?"

Given that G~q~PCR signaling is the main mechanism for decreasing membrane PIP~2~ levels and our evidence that PIP~2~ depletion increases TRPV4 channel activity (\~6-fold) in the absence of a TRPV4 agonist, we would argue that G~q~PCR agonists are the major physiological activators of TRPV4 in brain cECs. This aligns well with our ongoing studies using transgenic mice expressing a genetically encoded Ca^2+^ indicator, which show that G~q~PCR-stimulated TRPV4 channel activity is responsible for \~50% of the large, transient cEC Ca^2+^ signals induced by neural activity in vivo (Longden et al., World Congress of Microcirculation 2018). These data support the concept that low levels of TRPV4 channel activity induced by G~q~PCR agonists in the brain microenvironment can cause significant increases in intracellular Ca^2+^. Thus, although there may be endogenous direct activators of TRPV4 channels in the brain in addition to G~q~PCR agonists, they are not needed to support the physiological function of these channels.

2\) "Even upon PIP~2~ depletion whole-cell NP~o~ is only \~0.2 (amounting to a single-channel P~o~ of \~0.001), which is negligible channel activity."

The idea that a natural activator of TRPV4 currents in vivo is needed because NP~o~ is so low -- even with PIP~2~ depletion -- misses the very important point that even "negligible" TRPV4 activity is sufficient for this channel to exert its physiological functions. In fact, in a very real sense, mechanisms that *suppress* TRPV4 activity may be more important to the role of this channel in endothelial cells than those that activate it. Our previous studies highlight this point, demonstrating that exceedingly low levels of endothelial TRPV4 channel activity -- equivalent to that produced by activation of 1--2 channels per cell -- are capable of causing maximal dilation of systemic arteries (Sonkusare et al., 2012; 2014). Moreover, our computational modeling efforts show that the increase in TRPV4 current induced by G~q~PCR stimulation---from \~80 fA in the PIP~2~-suppressed state (at -40 mV) to \~400--500 fA with G~q~PCR stimulation -- would effectively short circuit K^+^-induced hyperpolarization, reinforcing the importance of constraints on TRPV4 activation for the operation of this key neurovascular coupling (NVC) mechanism. Importantly, our results described in response to comment 1.1, above, also confirm that PIP~2~ depletion alone is sufficient to produce physiologically meaningful TRPV4 channel activation. We have clarified these quantitative aspects in the revised manuscript.

3\) "Is PIP~2~ required for some modes of channel activation?"

As the reviewers indicate, one group (Suetsugu and colleagues, Nat Commun) reported that PIP~2~ is inhibitory towards all modes of activation, whereas another group (Valverde and colleagues, PNAS) reported that PIP~2~ is required for heat-, hypotonicity- and epoxyeicosatrienoic (EETs)-induced activation, but not for 4-αPDD--induced activation. Our results indicate that, in the absence of any agonist, PIP~2~ depletion increases TRPV4 channel open probability about 6-fold. In the presence of either of two distinct synthetic agonists, GSK101 or 4-αPDD (new supplementary figure), PIP~2~ depletion also increases TRPV4 channel activity about 6-fold. In response to the reviewers' comment, we tested the purported physiological activator of TRPV4 channels, 11,12-EET, and found that it activated TRPV4 currents even in the absence of any dialyzed PIP~2~ (Figure 3---figure supplement 2 in the revised manuscript), a result that contrasts with that of Garcia-Elias et al. (2013). We chose 11,12-EET because it has been implicated in NVC and is thought to transduce the effects of osmolarity (Garcia-Elias et al., 2013). (We did not test heat in excised patches because giga-ohm seals on cECs are unable to withstand temperature elevation.) Collectively, our results support the concept that PIP~2~ suppresses TRPV4 channel activity independent of the mode of activation, and are congruent with the results of Takahashi et al., (2014).

> 2\) Discussion:
>
> In a previous study, the group demonstrated that extracellular K^+^ increases activate cEC Kir channels resulting in an upstream hyperpolarizing current which mediated capillary-to-arteriole dilation (Nat. Neurosci, 2017). In a follow up study, the authors showed that PIP~2~ is a molecular regulator of Kir2.1 channels and that G~q~PCR activation impairs capillary-to-arteriole electrical signaling by depleting PIP~2~ (PNAS, 2018). In the current study the idea that G~q~PCR signaling can regulate (via PIP~2~) the activation of opposing signaling pathways suggests that activation of these receptors stops neuronal activity-evoked changes in blood flow. However, this is contradictory to earlier evidence by Lacroix et al. (2015), demonstrating an important role for COX-2 derived PGE~2~ in the NVC response. The authors cite this work, but do not explain how their proposed mechanism relates to the published findings on PGE2 and/or other G~q~PCR agonists. Would all G~q~PCR impair or retard the upstream hyperpolarization initiated by K^+^? Would this pathway be more relevant during pronounced ischemia? Or is it relevant under physiologic conditions? A thorough investigation of this question is beyond the scope of the present work, but a more detailed discussion of unresolved issues would be appreciated.

The question of whether G~q~PCR activation, particularly by PGE~2~, mediates NVC or serves to interrupt neuronal activity-evoked changes in blood flow, as speculated here, reveals limitations in our current understanding of how various features of neuronal signaling to the vasculature interact to create the meta phenomenon of activity-dependent control of blood flow distribution, as reflected in BOLD-fMRI measurements. On theoretical grounds, our current and previous (Harraz et al., 2018) findings support the idea that G~q~PCR signaling in capillary endothelial cells impedes electrical signaling through PIP~2~-depletion--mediated deactivation of Kir2.1 channels and enhancement of depolarizing currents through TRPV4 channels. In this sense, local G~q~PCR signals would act as "stop signs" in the pathway of electrical signaling, and could thereby conceivably sculpt the extent and directionality of signaling. However, we also have evidence that direct application of PGE~2~ to capillary extremities in an ex vivo capillary-parenchymal arteriole preparation acts via an as-yet unidentified mechanism to cause dilation of the upstream arteriolar segment, consistent with a contribution of PGE~2~ to NVC at the capillary level (Dabertrand, Brayden & Nelson, 2015 - Society of General Physiologists Symposium, abstract published in J Gen Physiol 146(3): 264). (As we reported previously (Dabertrand et al. J Cereb Blood Flow Metab. 2013; 33(4):479-82), direct application of PGE~2~ to arterioles causes arteriolar constriction.) Thus, we would suggest that these two functions -- NVC mediator and "stop sign" - are not necessarily mutually exclusive. We would also note that G~q~PCR activation would lead to an elevation of capillary endothelial cell \[Ca^2+^\]~i~, which should activate nitric oxide (NO) synthase to cause the production of NO, providing an additional mechanism by which PGE~2~ signaling might relax adjacent smooth muscle or contractile pericytes and contribute to NVC.

As indicated in Figure 5---figure supplement 2 in the original manuscript, the G~q~PCR agonist carbachol exerts an effect comparable to that of PGE~2~, whereas the PAR-2 ligand SLIGRL and the purinergic receptor agonist ATP had no effect. The absence of an effect of SLIGRL may reflect the absence of PAR-2 in brain capillary endothelial cells, as suggested by a previous transcriptomic study (Vanlandewijck et al., 2018). The inability of ATP to enhance TRPV4 channel activity is more difficult to explain, but is apparently not attributable to the absence of an appropriate P2Y receptor in capillary endothelial cells since ATP is capable of inhibiting Kir currents in these cells (Harraz et al., 2018). Thus, although there is some degree of generalizability, there may be more to the story than the simple ability to signal through a G~q~PCR.

In terms of the physiological context in which this pathway operates, our working assumption is that this stop sign-like function acts to shape Kir-mediated electrical signaling under physiological conditions. We would further predict that ischemia acts through a reduction in intracellular ATP to favor TRPV4 signaling over Kir2.1 signaling.
